GMF-1A3 / Gundersen Medical Foundation - LARVOL DELTA

Anti-tumor efficacy of GMF-1A3-MMAE, an antibody drug conjugate targeting cell surface cleaved Amphiregulin in endocrine-resistant breast cancer. (AACR-NCI-EORTC 2023) - No abstract available

Clinical • Breast Cancer • Oncology • Solid Tumor

Anti-tumor efficacy of GMF-1A3, an MMAE-based antibody drug conjugate targeting cell surface cleaved Amphiregulin in breast cancer (AACR 2023) - "We further demonstrate that these antibodies recognize the Amphiregulin neo-epitope in formalin fixed paraffin embedded tumor tissue, suggesting their utility as a companion diagnostic for patient selection. A pan-cancer tissue microarray analysis indicates that the target is commonly detected (> 50% of cases) in breast, prostate, liver and lung cancer."

Clinical • Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Oncology • Solid Tumor • ADAM17 • EGFR • ER